Dr. Daniel Santillano, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Texas A & M University System, Hsc, College of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 163
Licensed in Texas since 2008, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Texas A & M University System, Hsc, College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
TX license N0434 (first issued 2008; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Methodist Hospital San Antonio, TX
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 163
- Services billed
- 947
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 651 | 194 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 518 | 179 |
| Hospital discharge day management, more than 30 minutes | 185 | 165 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 128 | 122 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 122 | 116 |
| Hospital discharge day management, 30 minutes or less | 42 | 42 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoprolol Succinate Other prescribers in San Antonio, TX | 73 |
| Rosuvastatin Calcium Other prescribers in San Antonio, TX | 54 |
| Tramadol Hcl Other prescribers in San Antonio, TX | 53 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in San Antonio, TX | 40 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in San Antonio, TX | 35 |
| Amiodarone Hcl Other prescribers in San Antonio, TX | 30 |
| Metoprolol Tartrate Other prescribers in San Antonio, TX | 19 |
| Furosemide Other prescribers in San Antonio, TX | 17 |
| Carvedilol Other prescribers in San Antonio, TX | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $153 in total to this clinician.
| Novo Nordisk Inc | $153 |
|---|
| Food and Beverage | $153 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 8 companies. The companies reported $1,960,018 in research payments for these studies, mostly to the institutions running them.
- A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/…
Boehringer Ingelheim International GmbH - A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05519475 - A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company · Completed · NCT06047548 - A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals · Active, not recruiting · NCT03900429 - Evaluation of the dexcom continuous glucose monitor (cgm) and continuous lactate monitor (clm) in liver disease
Dexcom, Inc. - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Gilead Sciences, Inc. - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial
Boehringer Ingelheim International GmbH - 17 b-hydroxysteroid dehydrogenase type 13 minimization for the treatme
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.